|
Frank Bobe was named Executive Vice President and Chief Business Officer of Alseres in April 2007. Dr. Bobe has over 20 years of biotechnology and pharmaceutical industry experience. He joins Alseres from BioAxone Therapeutic, Inc. of Canada, where he served as President and Chief Executive Officer since March 2005. In addition to overseeing BioAxone's clinical trial of Cethrin in acute spinal cord injury, Dr. Bobe was responsible for guiding BioAxone's corporate strategy, developing its operating plan, and advancing its technical development platforms. Dr. Bobe played a key role in BioAxone's licensing of Cethrin and related intellectual property and technology to Alseres for nerve repair therapies following debilitating injuries to the spinal cord. Prior to joining BioAxone, Dr. Bobe was Chief Executive Officer and Country Head of the South Korean affiliate of Novartis AG, where he successfully launched several brands, implemented alliances with local and global partners and built a new management team. Prior to joining Novartis Korea, Dr. Bobe held operational management and global corporate leadership positions at Novartis AG, with increasing responsibilities in preclinical research, sales and marketing and general management. Dr. Bobe holds a Ph.D. in Bio-organic Chemistry from the University of California at Davis and completed a postdoctoral research fellowship in biochemistry in the laboratory of Nobel Laureate Prof. Bruce Merrifield, Rockefeller University, New York. Dr. Bobe also holds an MBA from INSEAD in Fontainebleau, France. | 